Drug Trial Radar · NCT06581432
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
588
Planned (sponsor's estimate)
Start
Oct 11, 2024
Primary completion
Nov 30, 2028
Study completion Dec 29, 2028
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Sep 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study. The purpose of this study is to find out whether a medicine called zongertinib helps people with advanced cancers with HER2 alterations. HER2 alterations can cause cancer. Zongertinib inhibits HER2. Participants are put into groups based on the type of advanced cancer they have, the type of HER2 alterations they have, and the dose of zongertinib they receive. Depending on the group they are in, participants take 1 of 2 different doses of zongertinib each day. Participants can continue the treatment as long as they benefit from it and can tolerate it. Participants visit the study site regularly. During many of the visits, the doctors check the size of the tumour and whether it has spread to other parts of the body. During all the visits, the doctors check participants' health and take note of any unwanted effects.
Conditions
- Solid Tumours
Interventions
ZongertinibDrug
Zongertinib
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients with objective response (OR)Time frame: Up to 51 months
Locations
93 sites in 16 countries. Site status is shown where the registry gives one.
Alaska Oncology and Hematology, LLC
Anchorage, Alaska · Recruiting
University of Arizona Comprehensive Cancer Center
Tucson, Arizona · Completed
Precision NextGen Oncology
Beverly Hills, California · Recruiting
Scripps Cancer Center Torrey Pines
La Jolla, California · Recruiting
Valkyrie Clinical Trials
Los Angeles, California · Recruiting
Yale University School of Medicine
New Haven, Connecticut · Recruiting
BRCR Global - Tamarac
Tamarac, Florida · Recruiting
Illinois Cancer Specialists
Arlington Heights, Illinois · Recruiting
Community MD Anderson Cancer Center - East Medical Oncology
Indianapolis, Indiana · Recruiting
Maryland Oncology Hematology, Columbia
Columbia, Maryland · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Completed
Presbyterian Healthcare Services
Albuquerque, New Mexico · Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
Memorial Sloan-Kettering Cancer Center
New York, New York · Recruiting
Taylor Cancer Research Center
Maumee, Ohio · Recruiting
Alliance Cancer Specialists, PC, Wynnewood
Wynnewood, Pennsylvania · Recruiting
Sarah Cannon Research Institute at Mary Crowley
Dallas, Texas · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Texas Oncology - Plano West
Plano, Texas · Recruiting
Virginia Cancer Specialists, PC
Fairfax, Virginia · Recruiting
Macquarie University
Macquarie Park, New South Wales, Australia · Recruiting
GenesisCare North Shore
St Leonards, New South Wales, Australia · Recruiting
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia · Recruiting
Cancer Research South Australia
Adelaide, South Australia, Australia · Recruiting
St John of God Subiaco Hospital
Subiaco, Western Australia, Australia · Recruiting
Cliniques Universitaires Saint-Luc
Brussels, Belgium · Recruiting
Universitair Ziekenhuis Antwerpen
Edegem, Belgium · Recruiting
Cross Cancer Institute (University of Alberta)
Edmonton, Alberta, Canada · Recruiting
BC Cancer Agency - Vancouver
Vancouver, British Columbia, Canada · Recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
Centre Hospitalier de l'Universite de Montreal (CHUM)
Montreal, Quebec, Canada · Recruiting
McGill University Health Centre (MUHC)
Montreal, Quebec, Canada · Completed
Peking University First Hospital
Beijing, China · Recruiting
Hunan Province Tumor Hospital
Changsha, China · Not yet recruiting
Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
Hangzhou, China · Recruiting
Anhui Provincial Cancer Hospital
Hefei, China · Recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, China · Recruiting
Nanjing Drum Tower Hospital
Nanjing, China · Not yet recruiting
Shanghai East Hospital
Shanghai, China · Recruiting
Shanghai GoBroad Cancer Hospital
Shanghai, China · Recruiting
Showing 40 of 93 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.